A
Abolis Biotechnologies
Biotech & Life Sciences · Évry-Courcouronnes, France · Founded 2014
Designs, Builds and Secure novel bio-processes for renewable chemical production with the help of engineered microbes MoreLess
Abolis is an industrial biotechnology company specializing in the development of bioproduction processes for chemical molecules via biomass fermentation. The company serves clients in the Chemical, Pharma, Cosmetic, and Food industries, addressing the challenge of producing ingredients and raw materials sustainably from economic, environmental, and societal perspectives. Abolis leverages its expertise in synthetic biology, informatics, robotics, fermentation, and analytical chemistry to create bio-based and clean alternatives to harmful chemicals. The business model revolves around providing tailored fermentation solutions that transform sugars into specific molecules of interest for their clients. Revenue is generated through project-based collaborations and the commercialization of proprietary bioprocess technologies.
Keywords: Industrial biotechnology, bioproduction, fermentation, biomass, sustainable, synthetic biology, chemical molecules, bio-based, environmental impact, tailored solutions.
Company overview
Abolis Biotechnologies company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2014
- Headquarters
- Évry-Courcouronnes, France
- Employees
- 69
- Open positions
- 11
- Dealroom signal
- 87.1
Valuation & funding
Abolis Biotechnologies funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Sep 2024 | $39M | $154M | Icos Capital · Liberset · Evonik Venture Capital · L'Oreal BOLD | ↗ |
| SEEDEquity / VC | Apr 2017 | $1.2M | $4.8M | Undisclosed | — |
| SPINOUT✓Other financing | Apr 2014 | $0 | — | SATT LUTECH · Evry-Val d'Essonne University - Paris-Saclay University · Sorbonne University · Paris-Saclay University | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 67 |
| 2025 | 60 |
| 2024 | 43 |
| 2023 | 42 |
| 2022 | 39 |
| 2021 | 32 |
| 2020 | 23 |
Growth signals
Abolis Biotechnologies website traffic
Latest recorded traffic for Abolis Biotechnologies is 1.5K monthly website visits, up 102.7% over the last three months. Abolis Biotechnologies's team grew 15% over the past year.
Hiring
Open positions at Abolis Biotechnologies
Current openings linked to this company in Dealroom.
Comparisons
Abolis Biotechnologies compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Abolis Biotechnologies's talent
Source: Dealroom Talent Intelligence.
Investors
11 investors on Abolis Biotechnologies's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Abolis Biotechnologies has talent and traffic
team presence
In the news
Latest news about Abolis Biotechnologies
Recent press, funding announcements, and product moves mentioning Abolis Biotechnologies — open to read from the original sources.
Market sentiment
What the market is saying about Abolis Biotechnologies
An AI-synthesized read of the highest-engagement posts about Abolis Biotechnologies on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Abolis Biotechnologies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.